Exane Derivatives’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Exane Derivatives’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$81.1K	Buy	1,017 +439	+76%	+$41.6K	0.05%	282
2022 Q1	$60.8K	Buy	+578	New	+$56.3K	0.02%	547
2017 Q1	–	Sell	-1	Closed	-$16	–	704
2016 Q4	$16	Hold	1	–	–	﹤0.01%	623
2016 Q3	$18	Hold	1	–	–	﹤0.01%	605
2016 Q2	$16	Sell	1 -9,999	-100%	-$162K	﹤0.01%	531
2016 Q1	$166K	Buy	+10,000	New	+$175K	0.02%	207

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Exane Derivatives's HZNP Position: Q2 2022 in Review

Exane Derivatives increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 76% in Q2 2022, buying an estimated $41.6K and bringing the position to 1,017 shares worth $81.1K. The position accounts for 0.05% of the portfolio, ranked #282.

Exane Derivatives first reported a position in HZNP in Q1 2016 and has held it in 6 quarters since. The position peaked at $166K in Q1 2016. 614 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Exane Derivatives held 1,017 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $81.1K as of Q2 2022.
Exane Derivatives bought 439 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $41.6K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.05% of Exane Derivatives's portfolio in Q2 2022, its #282 holding.
Exane Derivatives first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2016 and has held it in 6 quarters since.
Exane Derivatives's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $166K in Q1 2016.
614 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.